Pharmacogenetic Effect on the Pharmacodynamics of Glibenclamide
- Conditions
- Diabetes
- Registration Number
- NCT01242137
- Lead Sponsor
- Assaf-Harofeh Medical Center
- Brief Summary
Glibenclamide is metabolized by the hepatic enzyme P450 CYP2C9 to less active form. Polymorphism of this enzyme demonstrated clinical significance when examined on other drugs from the sulfonylurea drug family, to whom Glibenclamide is included.
The investigators assumption is that patients with less active alleles of the enzyme may show lower dose requirements of the drug for glycemic control, when compared to patients homozygotes to wild-type alleles.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
- Tx with metformin and glibenclamide
Exclusion Criteria
- Tx which affecting the P450 2C9 action
- Renal failure
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method HbA1c 2 years
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Assaf Harofe Medical Center
🇮🇱Beer Yakov, Israel